LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) ("PharmaCyte†or the "Companyâ€) today provided an update on its financial position. As reported in the Company's Quarterly Report on Form 10-Q for the quarter ended July 31, 2026 (PMCB's fiscal year ends April 30), PharmaCyte held total assets of approximately $36.7 million, including approximately $17.7 million in cash and cash equivalents. Stockholders' equity totaled approximately $27.5 million as of July 31, 2026. PharmaCyte. ...